ARCT
Arcturus Therapeutics Holdings Inc
NASDAQ: ARCT · HEALTHCARE · BIOTECHNOLOGY
$12.07
+7.48% today
Updated 2026-10-28
Market cap
$293.89M
P/E ratio
—
P/S ratio
10.01x
EPS (TTM)
$-3.33
Dividend yield
—
52W range
$6 – $24
Volume
1.1M
Arcturus Therapeutics Holdings Inc (ARCT) Financial Forecast & Price Target 2030
Revenue-driven projection model with historical context.
Price target summary
Current price
$12.07
12-Month target
—
2030 Target
—
Intrinsic (DCF)
$17.59
Financial forecast
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 | 2027 (E) | 2028 (E) | 2029 (E) | 2030 (E) |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.0B | $0.2B | $0.2B | $0.1B | $0.1B | $0.1B | $0.1B | $0.1B | $0.1B |
| EPS | — | — | — | — | — | — | — | — | — |
CAGR applied: 20.00% (capped 20%) · P/E: 25.00x (capped 25x) · Margin: 0.00%
Methodology
CAGR-based projection model. Research-backed estimates are being generated — check back soon for analyst consensus and management guidance.